Resmed has launched its NightOwl home sleep apnea test (HSAT) in the U.S. The U.S. Food and Drug Administration (FDA)-cleared HSAT offers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the home, the company said.

NightOwl leverages a small sensor worn on the fingertip and accompanying digital platforms for both individuals and providers. The disposable HSAT device records up to ten nights of sleep data for a single patient, capturing night-to-night variability and offering a comprehensive view of sleep patterns.

Sleep data is then remotely sent to a cloud-based diagnostic platform for physicians to analyze and review. Resmed believes this can enable quick interpretation, streamline diagnostic workflows, and help receive more timely diagnoses.

Raw patient data is autoscored with an algorithm clinically validated against polysomnography (PSG). It integrates with leading sleep lab management software and pairs with the company’s myAir app for step-by-step guidance throughout testing.

NightOwl leverage peripheral arterial tonometry, a noninvasive method that measures blood flow changes, oxygen saturation, and pulse rate changes to spot OSA. According to a multicenter validation study, NightOwl results using peripheral arterial tonometry showed close agreement with expert scored sleep lab testing PSG in its estimate of sleep apnea severity and clinical performance.

“Now more than ever, people want healthcare experiences that are easy, convenient, and accessible, however, navigating sleep apnea testing can be complex,” said Carlos M. Nunez, MD, chief medical officer at Resmed. “With NightOwl, people can easily complete a sleep apnea test from the comfort of home using just a fingertip sensor and a smartphone. It also simplifies the process for providers. This is a meaningful step forward in Resmed’s mission to deliver life-changing health technology that people love.”